Moderna Hits New High After 14% Friday Jump, Trading Far Above Analyst Targets

MRNA closed Friday at $225, up 14.2%, a fresh 52-week high that extends one of the market's biggest rallies of 2026. The shares have gained more than 500% this year, The Motley Fool's Adria Cimino wrote, noting that the stock now trades about 61% above Wall Street's average price target.

The driver is intismeran autogene, the personalized cancer vaccine Moderna is developing with MRK. Combined with Merck's Keytruda, it met its primary endpoint in a Phase 3 melanoma trial. The result was announced on Aug. 19, when the shares jumped 177%. Friday's move came as Moderna joined the Nasdaq-100, alongside a New York Times report on a public-private cancer-vaccine effort and a Bank of America price-target increase to $200, according to Stocktwits and other market coverage.

Valuation is the debate. SentiSense consensus data show an average price target of $122.67 across 18 analysts, with a range of $45 to $200 and a Hold rating, well below Friday's close. Citi rates the stock Sell with an $80 target, while Bank of America is Neutral at $200. The Motley Fool article also cautions that personalized vaccines are not easy to produce at scale.

With efficacy already shown in the Phase 3 trial, the next catalysts are detailed trial data, a regulatory filing timeline and evidence that Moderna can manufacture individualized doses at commercial scale. With analyst targets this far below the share price, the stock is exposed to sharp revisions in either direction.